Dynavax Technologies (DVAX) Q4 2024 earnings summary

Executive summary

• Achieved record HEPLISAV-B net product revenue of $268.4M in 2024, up 26% year-over-year, with Q4 revenue of $71.1M, up 39% year-over-year.

• U.S. HEPLISAV-B market share increased to 44% by end of 2024, targeting at least 60% by 2030.

• Advanced clinical pipeline with shingles and plague vaccine programs, including completed Phase 1/2 shingles trial enrollment and new $30M DoD agreement for plague vaccine.

• Returned capital to shareholders via $200M share repurchase program, with $100M completed and full completion expected by end of 2025.

• Maintained strong liquidity with $714M in cash and equivalents at year-end 2024.

Financial highlights

• FY 2024 total revenues were $277.2M, up 19% year-over-year; Q4 revenues were $72.0M, up 30% year-over-year.

• HEPLISAV-B gross margin improved to 82% in 2024 from 76% in 2023.

• FY 2024 GAAP net income was $27.3M, with Q4 net income of $7.1M.

• Adjusted EBITDA for 2024 was $52M, up over 300% year-over-year; Q4 adjusted EBITDA was $13.4M, up 225% year-over-year.

• Ended 2024 with $713.8M in cash, equivalents, and marketable securities.

Outlook and guidance

• 2025 HEPLISAV-B net product revenue expected at $305M–$325M, representing 17% year-over-year growth at midpoint.

• Adjusted EBITDA for 2025 projected to be at least $75M.

• Long-term HEPLISAV-B U.S. market opportunity projected to exceed $900M by 2030, with at least 60% market share.

• Double-digit annual growth in HEPLISAV-B net sales expected through 2030.

• Key clinical milestones in 2025 include top-line results for shingles vaccine and initiation of plague vaccine Phase 2.